BRIEF-Beam Therapeutics Announces Progress In Hematology And Genetic Disease Franchises

Reuters01-13

BRIEF-Beam <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Progress In Hematology And Genetic Disease Franchises

Jan 13 (Reuters) - Beam Therapeutics Inc BEAM.O:

BEAM THERAPEUTICS ANNOUNCES PROGRESS IN HEMATOLOGY AND GENETIC DISEASE FRANCHISES AND OUTLINES KEY 2025 ANTICIPATED CATALYSTS
EXPECTS TO DOSE 30 PATIENTS AND PRESENT DATA BY MID-2025
INITIAL DATA FROM BEAM-302 TRIAL EXPECTED IN FIRST HALF 2025
DOSING TO COMMENCE IN BEAM-301 TRIAL IN EARLY 2025
CASH RUNWAY EXPECTED TO SUPPORT OPERATIONS INTO 2027
OVER 40 ADULT SICKLE CELL PATIENTS ENROLLED IN BEACON TRIAL

Source text: ID:nGNX10kVtv

Further company coverage: BEAM.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2503304195?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-13 21:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503304195","market":"us","top_or_hot":-1,"title":"BRIEF-Beam Therapeutics Announces Progress In Hematology And Genetic Disease Franchises","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Progress In Hematology And Genetic Disease Franchises </title></head><body><p><span>Jan 13 (Reuters)</span><span> - </span>Beam Therapeutics Inc <span>BEAM.O</span>:</p><ul><li><p>BEAM THERAPEUTICS ANNOUNCES PROGRESS IN HEMATOLOGY AND GENETIC DISEASE FRANCHISES AND OUTLINES KEY 2025 ANTICIPATED CATALYSTS</p></li><li><p>EXPECTS TO DOSE 30 PATIENTS AND PRESENT DATA BY MID-2025</p></li><li><p>INITIAL DATA FROM BEAM-302 TRIAL EXPECTED IN FIRST HALF 2025</p></li><li><p>DOSING TO COMMENCE IN BEAM-301 TRIAL IN EARLY 2025</p></li><li><p>CASH RUNWAY EXPECTED TO SUPPORT OPERATIONS INTO 2027</p></li><li><p>OVER 40 ADULT SICKLE CELL PATIENTS ENROLLED IN BEACON TRIAL</p></li></ul><p>Source text: <span>ID:nGNX10kVtv</span></p><p>Further company coverage: <span>BEAM.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Beam Therapeutics Announces Progress In Hematology And Genetic Disease Franchises</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Beam Therapeutics Announces Progress In Hematology And Genetic Disease Franchises\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-13 21:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nTUA7L5W8J:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Beam Therapeutics Announces Progress In Hematology And Genetic Disease Franchises Jan 13 (Reuters) - Beam Therapeutics Inc BEAM.O:BEAM THERAPEUTICS ANNOUNCES PROGRESS IN HEMATOLOGY AND GENETIC ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nTUA7L5W8J:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4556","symbol_name":"基因编辑","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nTUA7L5W8J:1","article_id":"2503304195","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503304195","pubTimestamp":1736775448,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Beam Therapeutics Announces Progress In Hematology And Genetic Disease Franchises Jan 13 (Reuters) - Beam Therapeutics Inc BEAM.O:BEAM THERAPEUTICS ANNOUNCES PROGRESS IN HEMATOLOGY AND GENETIC D","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4556":"基因编辑","BK4588":"碎股","BK4139":"生物科技","BK4505":"高瓴资本持仓","BEAM":"Beam Therapeutics, Inc.","BK4535":"淡马锡持仓","BK4585":"ETF&股票定投概念"},"translate_title":"BRIEF-Beam Therapeutics宣布血液学和遗传病特许经营取得进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BEAM":0.9},"content_text":"BRIEF-Beam Therapeutics Announces Progress In Hematology And Genetic Disease Franchises Jan 13 (Reuters) - Beam Therapeutics Inc BEAM.O:BEAM THERAPEUTICS ANNOUNCES PROGRESS IN HEMATOLOGY AND GENETIC DISEASE FRANCHISES AND OUTLINES KEY 2025 ANTICIPATED CATALYSTSEXPECTS TO DOSE 30 PATIENTS AND PRESENT DATA BY MID-2025INITIAL DATA FROM BEAM-302 TRIAL EXPECTED IN FIRST HALF 2025DOSING TO COMMENCE IN BEAM-301 TRIAL IN EARLY 2025CASH RUNWAY EXPECTED TO SUPPORT OPERATIONS INTO 2027OVER 40 ADULT SICKLE CELL PATIENTS ENROLLED IN BEACON TRIALSource text: ID:nGNX10kVtvFurther company coverage: BEAM.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2503304195"}